SAN DIEGO, March 9, 2010 (GLOBE NEWSWIRE) — Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction. LIPO-102 is being studied for the treatment of exophthalmos using abdominal fat as a surrogate for periorbital fat. LIPO-102 was well-tolerated when administered weekly for 4 weeks into the subcutaneous abdominal fat of healthy subjects. Dose- and time-related reductions in abdominal circumference and skin-fold thickness measures were observed one (Week 5) and four (Week 
weeks after the treatment period. A reduction of 3.47 cm (p=0.017) in mean abdominal circumference was observed at Week 8 in subjects receiving the o…
Further information:
Related posts:
- Dr. Jay Calvert Introduces Fat Zapping Lipo-Laser
- Asymptomatic Achilles tendon pathology is associated with a central fat distribution in men and a peripheral fat distribution in women: a cross sectional study of 298 individuals
- The use of LeptiCore in reducing fat gain and managing weight loss in patients with metabolic syndrome
- Akebia Announces Initiation Of Phase 1b Clinical Study Of AKB-6548
- Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers
Posted in